Thorogood M, Hannaford P C
Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK.
Br J Obstet Gynaecol. 1998 Dec;105(12):1296-9. doi: 10.1111/j.1471-0528.1998.tb10008.x.
To examine the risk of multiple sclerosis in users of combined oral contraceptives.
Cohort study conducted between 1968 and 1996 using diagnostic data supplied by general practitioners
General practices throughout the United Kingdom.
Royal College of General Practitioners' Oral Contraception Study cohort of initially 46,000 women recruited during the late 1960s.
Directly standardised incidence rates of multiple sclerosis were calculated for current, former and never-users of oral contraceptives using first ever cases of multiple sclerosis reported by the general practitioners. The standardisation variables were age, parity, social class and smoking history. Five-year survival rates in the different contraceptive groups were calculated using standard life table techniques.
One hundred and fourteen first ever cases of multiple sclerosis had been reported by November 1996 during 564,000 woman-years of observation. The incidence rate in both current and former users was not materially different to that in never-users. Although based on limited evidence there was no suggestion that the five-year survival was affected by a woman's use of combined oral contraceptives.
These findings do not suggest a greatly elevated risk of multiple sclerosis during, or after, use of combined oral contraceptives.
研究复方口服避孕药使用者患多发性硬化症的风险。
1968年至1996年间进行的队列研究,使用全科医生提供的诊断数据。
英国各地的全科医疗诊所。
皇家全科医师学院口服避孕药研究队列,最初是在20世纪60年代末招募的46000名女性。
根据全科医生报告的首例多发性硬化症病例,计算口服避孕药当前使用者、既往使用者和从未使用者的多发性硬化症直接标准化发病率。标准化变量包括年龄、产次、社会阶层和吸烟史。使用标准生命表技术计算不同避孕组的五年生存率。
到1996年11月,在56.4万妇女年的观察期内,共报告了114例首例多发性硬化症病例。当前使用者和既往使用者的发病率与从未使用者的发病率没有实质性差异。虽然证据有限,但没有迹象表明女性使用复方口服避孕药会影响五年生存率。
这些研究结果并未表明在使用复方口服避孕药期间或之后患多发性硬化症的风险会大幅升高。